Risperdal Lawsuit Defendants Seek to Slow Growth of Pennsylvania Mass Tort

Published on March 6, 2017 by admin

Text-Size:A A A+


In a bid to slow the growth of Pennsylvania’s Risperdal mass tort, Janssen Pharmaceuticals is seeking to impose additional requirements on those who wish to bring new cases to the proceeding. In papers recently filed with the Philadelphia Court of Common Pleas, the drug maker proposed that prospective plaintiffs be required to include medical and prescription drug records with their Plaintiff Fact Sheets.

“Indeed, the court should consider the fact that the landscape and scope of this litigation is changing dramatically,” Janssen asserted in a memo dated February 22nd. “It is appropriate, indeed essential, that the court limit the exploding inventory in this program to cases that have the minimal good-faith basis required for a claim.”

According to The Legal Intelligencer, plaintiffs attorneys are opposed, and have called Janssen’s plan a bid t create a “pseudo-summary judgment procedure.”

2,000+ Risperdal Lawsuits in PA, 18,000+ Nationwide

Court records indicate that more than 2,000 Risperdal lawsuits have been filed in Philadelphia on behalf of individuals who experienced gynecomastia and other side effects allegedly associated with use of the atypical antipsychotic. Janssen’s parent company, Johnson & Johnson, recently reported that more than 18,000 Risperdal injury claims were pending in courts nationwide.

According to RXInjuryHelp.com, much of the litigation involving Risperdal centers on gynecomastia, a condition that causes men and boys to develop female-like breasts. According to these lawsuits, Risperdal stimulates the pituitary gland to overproduce prolactin, a hormone that plays a role in female breast development and lactation. Men and boys with high levels of prolactin may suffer from excess breast growth. Among other things, plaintiffs point out that the Risperdal label had once characterized gynecomastia as a rare complication that affected only about 1 in 1,000 patients. The prescribing information was eventually updated to state that there was a 2.3% rate of the condition in adolescents treated with the drug.

For two years now, the Pennsylvania litigation has been convening trials involving Risperdal and gynecomastia. Many of those cases have returned verdicts in favor of plaintiffs, with verdicts ranging from $500,000 to $70 million. Some cases have also been settled just prior to trial.

Bernstein Liebhard LLP is representing men and boys who allegedly developed gynecomastia due to Risperdal. If you or someone you care about had a similar experience, please call (888) 995-5099 to learn more about your legal options.